Matthew P. Goetz, MD
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Related Items
First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer
Chase Doyle
JHOP Web Exclusives published on October 15, 2018 in Breast Cancer
Working Together to Find the New Standard of Care
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Opportunities Are Abundant for Navigators in the Field of Genetics and Genomics
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Healthcare Team's Relationship to the Patient
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
The Navigator's Role in Genetic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Why Are Clinical Trials Important?
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Educating Oncology Professionals on Genetic and Genomic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Who Should Consider Genetic Testing?
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
What the Next Generation of Cancer Biomarkers May Involve
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
Last modified: December 8, 2017